Xenotransplantation of Porcine Kidneys in Brain-Dead Humans
In a brain-dead human decedent model, kidneys from genetically modified pigs were transplanted without hyperacute rejection and produced urine, demonstrating surgical feasibility and short-term function while exposing remaining barriers such as thrombotic microangiopathy and later antibody-mediated rejection.
Background
A persistent shortage of donor kidneys limits transplantation for patients with end-stage kidney disease, and genetically engineered pig organs have emerged as a potential solution. Brain-dead decedents were introduced as a preclinical human model to test the safety and feasibility of xenotransplantation without risking a living patient, bridging prior nonhuman primate studies and planned clinical trials.
Study design
In reported cases, investigators performed bilateral native nephrectomies in brain-dead decedents and transplanted kidneys from pigs carrying genetic modifications such as alpha-1,3-galactosyltransferase knockout, with serial biopsies and monitoring of urine output and kinetic estimated glomerular filtration rate. Standard clinically approved immunosuppression was used, and decedents were supported on ventilators for study periods ranging from roughly 54-74 hours up to a pre-planned 61-day study in later experiments.
Key findings
Across decedent experiments, the pig kidneys generally began producing urine shortly after reperfusion and showed no hyperacute rejection, with kinetic eGFR rising and serum creatinine falling in some recipients. However, findings included thrombotic microangiopathy, variable creatinine clearance, and, in the extended 61-day study, biopsy-confirmed antibody-mediated rejection around postoperative day 33 driven by donor-specific IgG and pre-existing xenoreactive T cells, which responded to plasma exchange, complement inhibition, and anti-thymocyte globulin.
Clinical implications
These decedent studies suggest that the barrier of hyperacute rejection can be overcome with gene editing and that pig kidneys can support physiologic function, paving the way toward phase I clinical trials in living patients. Commentators caution that the profound pathophysiologic changes of brain death and short observation windows complicate interpretation, and that pre-existing xenoreactive T cells, induced antibodies, complement activation, and potential porcine viral reactivation remain major challenges to be addressed before broad clinical application.
Category
Transplant
Source
NEJM
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.